Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tommaso Barba

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Frontiers in Psychiatry|June 28, 2023
Psychedelic therapy in the treatment of addiction: the past, present and futureRayyan Zafar, Maxim Siegel, Rebecca Harding, et al.
Eclinicalmedicine|January 7, 2025
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trialDavid Erritzoe, Tommaso Barba, Kyle T Greenway, et al.
Frontiers in Psychiatry|January 26, 2024
Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trialEllen James, David Erritzoe, Tiffanie Benway, et al.
Nature Medicine|February 16, 2026
A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trialDavid Erritzoe, Tommaso Barba, Tiffanie Benway, et al.
Neuroscience of Consciousness|April 22, 2025
Exploring 5-MeO-DMT as a pharmacological model for deconstructed consciousnessChristopher Timmermann, James W Sanders, David Reydellet, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Frontiers in Psychiatry|June 28, 2023
Psychedelic therapy in the treatment of addiction: the past, present and futureRayyan Zafar, Maxim Siegel, Rebecca Harding, et al.
Eclinicalmedicine|January 7, 2025
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trialDavid Erritzoe, Tommaso Barba, Kyle T Greenway, et al.
Frontiers in Psychiatry|January 26, 2024
Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trialEllen James, David Erritzoe, Tiffanie Benway, et al.
Nature Medicine|February 16, 2026
A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trialDavid Erritzoe, Tommaso Barba, Tiffanie Benway, et al.
Neuroscience of Consciousness|April 22, 2025
Exploring 5-MeO-DMT as a pharmacological model for deconstructed consciousnessChristopher Timmermann, James W Sanders, David Reydellet, et al.
Pageof 2